Holen Sie sich die Stockscreener-App
17.17
1.54%
0.26
Handel nachbörslich:
17.18
0.010
+0.06%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stocks With Rising Relative Price Strength: Stoke Therapeutics - MSN
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Stoke Therapeutics Skyrockets 25.57%—What’s Fueling This Biotech Surge? - AInvest
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. - PharmiWeb.com
Stoke Therapeutics shares rise 3.10% premarket after dosing first patient in Phase 3 trial of Zorevunersen for Dravet Syndrome. - AInvest
Stoke Therapeutics 2025 Q2 Earnings Net Income Cuts Loss by 8.6% - AInvest
Stoke Therapeutics Q2 Loss Narrows, Revenue Rises - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations - Investing.com
Stoke Therapeutics shares rise 2.73% after-hours following positive Q2 results and Phase 3 trial initiation. - AInvest
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative
Stoke Therapeutics Q2 2025 slides: Phase 3 Dravet trial underway, ADOA program advances - Investing.com Canada
Stoke's Dravet Syndrome Treatment Shows 3-Year Durability as Pivotal Trial Begins - Stock Titan
Can Stoke Therapeutics Inc. outperform under higher oil pricesStrong Support Zone Stocks - thegnnews.com
First patient dosed in Phase III trial of zorevunersen for Dravet syndrome - Clinical Trials Arena
Stoke Therapeutics shares fall 2.74% premarket after dosing first patient in Phase 3 EMPEROR study of zorevunersen. - AInvest
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - BioSpace
Stoke Therapeutics Earnings Preview: Analyst Expectations and Market Sentiments - AInvest
A Look Ahead: Stoke Therapeutics's Earnings Forecast - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Ariva
First Dravet syndrome patient dosed in Phase 3 trial of zorevunersen - Investing.com Canada
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com Australia
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial By Investing.com - Investing.com South Africa
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Institutional scanner results for Stoke Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Free Fundamental Growth Stock Analysis - Newser
Multi asset correlation models including Stoke Therapeutics Inc.Free Trend Following Strategy With Stop Loss - Newser
Can momentum traders help lift Stoke Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
Will Stoke Therapeutics Inc. bounce back from current supportLow Drawdown Stock Screener with Analysis - Newser
Stoke Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEquity Forecast with Predictive AI Screener - Newser
Stoke Therapeutics Inc. Outperforms Peers on Volume MetricsAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Stoke Therapeutics STOK 2025Q2 Earnings Preview Upside Potential on Innovative Fluorescence Applications - AInvest
Stoke Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Stoke Therapeutics to Host Q2 2025 Business and Financial Update Webcast and Conference Call. - AInvest
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - The Globe and Mail
Stoke Therapeutics Earnings Call to Reveal Latest Progress on Revolutionary Dravet Syndrome Treatment - Stock Titan
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - BioSpace
Published on: 2025-08-05 00:18:53 - beatles.ru
Combining machine learning predictions for Stoke Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Trendline Breach Raises Concern for Stoke Therapeutics Inc. InvestorsVerified Signal From Chart Patterns Detected - metal.it
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Maximize returns with strategic portfolio planning - Jammu Links News
Is Stoke Therapeutics Inc. a growth stock or a value stockRemarkable growth - Jammu Links News
Is it the right time to buy Stoke Therapeutics Inc. stockMaximize returns with expert trading insights - Jammu Links News
How many analysts rate Stoke Therapeutics Inc. as a “Buy”Invest confidently with data-driven strategies - Jammu Links News
What analysts say about Stoke Therapeutics Inc. stockRapid return acceleration - Jammu Links News
Does Stoke Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough results with expert guidance - Jammu Links News
How strong is Stoke Therapeutics Inc. company’s balance sheetMaximize your portfolio’s growth potential - Jammu Links News
How volatile is Stoke Therapeutics Inc. stock compared to the marketUnlock expert insights for smarter investing - Jammu Links News
How does Stoke Therapeutics Inc. compare to its industry peersRapid wealth accumulation - Jammu Links News
What catalysts could drive Stoke Therapeutics Inc. stock higher in 2025Double or triple returns - Jammu Links News
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):